La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock
September 09 2015 - 3:22PM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or
“La Jolla”), a leader in the development of innovative therapies
intended to significantly improve outcomes in patients suffering
from life-threatening diseases, today announced its intention to
offer and sell shares of its common stock in an underwritten
offering pursuant to its existing shelf registration statement. All
of the shares in the proposed offering are to be sold by La
Jolla.
Jefferies LLC is acting as the book-running manager for the
offering. La Jolla intends to grant the underwriters a 30-day
option to purchase additional shares of its common stock. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering.
La Jolla intends to use the net proceeds from the underwritten
offering for general corporate purposes, funding its ongoing and
future clinical trials, general and administrative expenses and
potential future acquisitions and other strategic purposes.
The securities described above are being offered pursuant to a
shelf registration statement (File No. 333-197092), including a
base prospectus, which was declared effective by the United States
Securities and Exchange Commission (“SEC”) on July 11, 2014. The
specific terms of the offering are described in a prospectus
supplement to be filed with the SEC in connection with the
offering. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction. The
offering will be made only by means of the prospectus supplement
and accompanying prospectus, copies of which may be obtained at the
SEC’s website at www.sec.gov, or by request at Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340,
e-mail: Prospectus_Department@Jefferies.com.
This press release contains statements relating to the proposed
offering that are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended.
Such statements involve risks and uncertainties, such as the risk
that the conditions to the closing of the offering will not be
satisfied. All forward-looking statements are based upon
information available to La Jolla on the date the statements are
first published. La Jolla undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company
focused on the discovery, development and commercialization of
innovative therapies intended to significantly improve outcomes in
patients suffering from life-threatening diseases. The Company has
several product candidates in development. LJPC-501 is La Jolla’s
proprietary formulation of angiotensin II for the potential
treatment of catecholamine-resistant hypotension. LJPC-401 is La
Jolla’s novel formulation of hepcidin for the potential treatment
of iron overload, which occurs as a result of diseases such as
hereditary hemochromatosis (HH), beta thalassemia and sickle cell
disease. LJPC-30Sa and LJPC-30Sb are La Jolla’s next-generation
gentamicin derivatives for the potential treatment of serious
bacterial infections and rare genetic disorders, such as cystic
fibrosis and Duchenne muscular dystrophy.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150909006680/en/
La Jolla Pharmaceutical CompanyGeorge F. Tidmarsh, M.D.,
Ph.D.President & Chief Executive OfficerPhone: (858)
207-4264Email: gtidmarsh@ljpc.comandDennis M. MulroyChief Financial
OfficerPhone: (858) 433-6839Email: dmulroy@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Apr 2024 to May 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From May 2023 to May 2024